Ixempra

Ixempra Uses, Dosage, Side Effects, Food Interaction and all others data.

Ixempra is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixempra is administered through injection, and will be marketed under the trade name Ixempra. Ixempra is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.

Trade Name Ixempra
Availability Prescription only
Generic Ixabepilone
Ixabepilone Other Names Aza-epothilone B, Azaepothilone B, Ixabepilone
Related Drugs Arimidex, Ibrance, Femara, Xeloda, Herceptin, Lynparza
Weight 15mg, 45mg,
Type Injection, Intravenous Powder For Injection
Formula C27H42N2O5S
Weight Average: 506.7
Monoisotopic: 506.281443634
Protein binding

67-77%

Groups Approved, Investigational
Therapeutic Class
Manufacturer Bristol-myers Squibb Pvt Ltd
Available Country India, United States,
Last Updated: September 19, 2023 at 7:00 am
Ixempra
Ixempra

Uses

Ixempra is a microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.

Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).

Ixempra is also used to associated treatment for these conditions: Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer

How Ixempra works

Binding of Ixempra to beta-tubulins (e.g. beta-III tubulin) stabilizes microtubules. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Like taxol, Ixempra binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules.

Food Interaction

  • Avoid grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of ixabepilone, which may increase its serum concentration.
  • Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of ixabepilone.

[Moderate] GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ixabepilone.

The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

MANAGEMENT: Patients treated with ixabepilone should avoid the consumption of grapefruit or grapefruit juice.

Half Life

52 hours

Elimination Route

Mostly fecal and some renal.

Innovators Monograph

You find simplified version here Ixempra

*** Taking medicines without doctor's advice can cause long-term problems.
Share